Benchmark Rings the Nasdaq Stock Market Opening Bell with Genelux Corporation


genelux logo rgb web tagline4

Genelux Corporation (Nasdaq: GNLX), a late clinical-stage biopharmaceutical company focused on developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types, visits the Nasdaq MarketSite in Times Square. In honor of the occasion, Thomas Zindrick, President and Chief Executive Officer, rings the Opening Bell.

See the video here.